重庆君药生物医药

Chongqing Junyao Biopharmaceutical is a Chinese biotechnology company established as a joint venture between Shanghai Junshi Biosciences and Suzhou Wangshan Wangshui Biopharmaceutical. The company is primarily focused on the development and commercialization of VV116 (Deuremidevir hydrobromide), an oral antiviral drug for the treatment of COVID-19. VV116 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase (RdRp) of the SARS-CoV-2 virus. Based in the Liangjiang New Area of Chongqing, the company serves as a key hub for the industrialization of Junshi's antiviral pipeline. Its efforts contributed to the conditional marketing authorization of VV116 in China. The company represents a strategic collaboration to accelerate the availability of innovative treatments for infectious diseases.